The EU regulatory transition is no longer a future problem for medical device manufacturers — it is happening now. May and November 2026 bring a cluster of hard deadlines under the EU Medical Device Regulation (MDR) 2017/745 and In Vitro Diagnostic Regulation (IVDR) 2017/746 that will determine which manufacturers can legally continue selling in the EU. Missing these dates does not trigger a warning — it triggers loss of market access.

Where the Transition Stands in 2026

Regulation (EU) 2023/607 extended the MDR transition timeline to protect against device shortages, pushing the final deadline for high-risk legacy devices to 31 December 2027 and lower-risk devices to 31 December 2028. A further amendment, Regulation (EU) 2024/1860, extended IVDR timelines for self-declared legacy IVDs. These extensions relieved pressure — but they created a false sense of security for many manufacturers still operating under MDD or IVDD certificates.

To qualify for the extended transition, manufacturers had to have lodged a formal conformity assessment application with a Notified Body by 26 May 2024 and signed a written agreement with that Notified Body by 26 September 2024 (MDR Article 120(3)). Manufacturers who missed those gates cannot access the extended period and must treat their legacy certificates as already expired (MedDeviceGuide, April 2026).

For those who do qualify, compliance with the underlying MDD or AIMDD must be maintained continuously throughout the transition — it is not a pause on regulatory obligations.

The 2026 Deadlines Manufacturers Face Now

26 May 2026 — Class III custom-made implantable devices (MDR). These devices received a separate grace period under Article 120(3)(f) MDR, but that period ends now. A QMS certificate from a Notified Body must be in place. Manufacturers who lodged an application by May 2024 and signed an agreement by September 2024 qualify for this extension — those who did not must cease EU market placement immediately (Casus Consulting, January 2026).

26 May 2026 — IVDR Class C legacy IVDs (self-declared). Under Regulation (EU) 2024/1860, manufacturers of self-declared Class C IVDs that previously required no Notified Body involvement under the old IVDD must have lodged a conformity assessment application by this date. Missing this deadline means the device loses its eligibility for the extended IVDR transition period entirely (Rookqs, May 2026).

28 May 2026 — EUDAMED becomes mandatory. On 27 November 2025, the European Commission published Commission Decision (EU) 2025/2371 confirming that four EUDAMED modules are fully operational. This triggered a six-month countdown. From 28 May 2026, Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance modules are no longer optional — they are required. Any new device placed on the EU market on or after this date must be registered in EUDAMED before placement. There is no grace period for new devices (DNV, March 2026).

28 November 2026 — Legacy device EUDAMED registration deadline. Devices already on the EU market before 28 May 2026 have until 28 November 2026 to complete EUDAMED registration. This is a structured six-month window, not an extension. If a legacy device becomes subject to a vigilance action or Field Safety Corrective Action before registration is complete, immediate registration is required regardless of this deadline (Rookqs, May 2026).

CRITICAL PREREQUISITE

Every EUDAMED obligation — device registration, certificate management, market surveillance — depends on first obtaining a Single Registration Number (SRN) through Actor Registration. Without a validated SRN, no other EUDAMED activity can proceed. Non-EU manufacturers must register through their EU Authorized Representative, whose Competent Authority then validates the registration and issues the SRN (osapiens, May 2026).

What Manufacturers Must Do Right Now

The steps below apply regardless of whether you are managing MDR or IVDR legacy transition, or both.

  1. Confirm your transition eligibility. Verify that your Notified Body application was lodged by 26 May 2024 and that a signed written agreement is in place dated no later than 26 September 2024. If either condition is not met, the extended transition period does not apply to your legacy devices and fresh MDR/IVDR applications must be submitted immediately.
  2. Complete EUDAMED Actor Registration. If your organisation does not yet have an SRN, this is the single most urgent action. Registration must be validated by the relevant Competent Authority before the SRN is issued — that validation takes time. Non-EU manufacturers must coordinate with their EU Authorised Representative to initiate this process. Every other EUDAMED deadline depends on having an active SRN.
  3. Register all new devices in EUDAMED before placement. From 28 May 2026, any device new to the EU market must be registered in the UDI/Device module before it can be legally placed. Ensure technical documentation, Basic UDI-DI data, and trade names are consistent across all documentation and your EUDAMED submission.
  4. Register legacy devices by 28 November 2026. Audit your full product portfolio now. Identify which devices were on the EU market before 28 May 2026 and require retrospective EUDAMED entry. Manufacturers with large portfolios should evaluate machine-to-machine (M2M) integration with EUDAMED via XML-based protocols to avoid manual data entry bottlenecks (Celegence, December 2025).
  5. Manage Notified Body capacity proactively. Fewer than 40 Notified Bodies are currently designated under MDR, and approximately 19 under IVDR. Review queues are long. Manufacturers who have not yet secured audit slots for their full MDR/IVDR conformity assessment — beyond just the application agreement — should treat Notified Body availability as a critical path risk. The written agreement is the minimum; full certification must follow within the transition window.
  6. Maintain ongoing MDD/AIMDD compliance. Transitioning manufacturers must continue to comply with the requirements of the underlying Directive throughout the legacy period. MDR Article 120(3) also requires implementation of post-market surveillance and vigilance processes — even before full MDR certification is achieved.
  7. Plan for no sell-off deadline. Regulation (EU) 2023/607 removed the sell-off date from both MDR Article 120(4) and IVDR Article 110(4). Devices lawfully placed on the EU market during the transition period may continue to be made available without a time limit (subject to shelf life). This removes one pressure point — but does not affect the manufacturing and placement deadlines above.

The application and written agreement deadlines were prerequisites, not the finish line. Manufacturers who met them still need to complete full MDR or IVDR conformity assessment before their transition window closes — and Notified Body capacity is the variable most likely to cause a miss.

The 2026 deadlines represent the regulatory transition entering its final, non-negotiable phase. Manufacturers who secured their Notified Body agreements in 2024 still have a path to the EU market — but only if EUDAMED registration, portfolio audits, and conformity assessment timelines are actively managed now. Suplivia's verified manufacturer directory reflects MDR and IVDR certification status across listed manufacturers, providing buyers with real-time visibility into which suppliers hold valid EU market access.